The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 05, 2025
Filed:
Apr. 18, 2019
Applicant:
Baylor College of Medicine, Houston, TX (US);
Inventors:
Caroline Eva Arber Barth, Houston, TX (US);
Gagan Bajwa, Houston, TX (US);
Malcolm K. Brenner, Houston, TX (US);
Assignee:
Baylor College of Medicine, Houston, TX (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/00 (2006.01); A61K 40/11 (2025.01); A61K 40/32 (2025.01); A61K 40/42 (2025.01); A61K 45/06 (2006.01); A61K 48/00 (2006.01); A61P 35/00 (2006.01); C07K 14/47 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C12N 5/0783 (2010.01);
U.S. Cl.
CPC ...
A61K 45/06 (2013.01); A61K 40/11 (2025.01); A61K 40/32 (2025.01); A61K 40/424 (2025.01); A61P 35/00 (2018.01); C07K 14/4748 (2013.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C12N 5/0638 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/48 (2023.05); C12N 2510/00 (2013.01);
Abstract
Embodiments of the disclosure include methods and compositions related to improvements of T cell therapy. In particular embodiments, CD8+ T cell therapy is enhanced upon expression of transgenic E08αβ co-receptor in the CD8+ T cells. In certain embodiments, CD4+ T cells are rendered to have cytotoxic cell function for adoptive transfer upon expression of transgenic E08αβ co-receptor in the CD4+ T cells. In specific embodiments, TCR-expressing and E08αβ co-receptor-expressing CD4+ and CD8+ T cells are utilized in adoptive transfer.